0
FACTORIES
0
TOTAL FLOORSPACE, М2
>
0
BLN TABLETS/CAPSULES A YEAR
The company uses process and laboratory equipment from the world’s leading manufacturers.
Careful recruitment builds a strong team of highly qualified professionals.
High standards and commitment to quality enable the factory to be a firm leader in its segment.
The company implements the most advanced internal control methods ensuring full compliance with the GMP.
In 2022, PharmEco Group began the implementation of its project focused on setting up, in Technopolis Moscow, an import replacement production of biotech drugs called BIOJET.
Bioject will be engaged in design and production of biotechnological medications based on monoclonal antibodies in full cycle right from the manufacture of the active pharmaceutical substance.
The projected capacity of the enterprise is up to 120 kg of active biopharmaceutical substances and 5M vials of ready-to-use product a year. Production is expected to be launched in Q4 of 2023.